Tariffs initiate a new round of adjustment, with more "zero tariffs" coming
2024-01-09
Starting from January 1st of this year, a new round of tariff adjustments has been initiated, with "zero tariff" becoming a high-frequency term - implementing zero tariff on some anti-cancer drugs, rare disease drugs, drugs and raw materials, etc; The temporary import tax rate for lithium chloride, cobalt carbonate, and seed sweet corn has been reduced to zero; China and Nicaragua will immediately implement zero tariffs on products with approximately 60% of their respective tax items... Experts say that in recent years, China's total tariff level has continued to decrease, and more and more goods have entered the "zero tariff era". This is not only conducive to enhancing the linkage effect between domestic and international markets, enhancing people's well-being, benefiting enterprise development, maintaining the stability and smoothness of domestic industrial and supply chains, but also promoting high-level opening up to the outside world, Let the world share more opportunities for China's development. According to the latest 2024 tariff adjustment plan (hereinafter referred to as the "plan"), starting from January 1st, China will implement a temporary import tariff rate lower than the most favored nation rate for 1010 imported goods, including some anti-cancer drugs and resource goods. After reviewing this plan, the reporter found that some drugs and raw materials have been temporarily adjusted to zero import tax rates, such as anti-cancer drugs used to treat liver malignancies, rare disease drug raw materials used to treat idiopathic pulmonary hypertension, and inhaled ipratropium bromide solution, which can be widely used in clinical practice for the treatment of childhood asthma. "Implementing zero tariffs on some anti-cancer drugs, rare disease drugs, and raw materials can help reduce drug costs, alleviate the burden of drug expenses on patients, especially cancer patients, and provide more medication options to further protect people's lives and health." Zhang Jianping, Deputy Director of the Academic Committee of the International Trade and Economic Cooperation Research Institute of the Ministry of Commerce, said that in fact, in recent years' tariff adjustments, medicine has always been a key area for tax reduction, Many import tariffs on anti-cancer drugs, rare disease drugs, and related raw materials have been reduced to zero. On May 1, 2018, China adjusted import tariffs on some drugs and cancelled import tariffs on 28 drugs, including multiple types of imported anti-cancer drugs. The relevant measures quickly took effect. In October of that year, 17 anti-cancer drugs were included in the medical insurance reimbursement list, with an average decrease of 56.7% compared to the previous average retail price. Since then, China has successively cancelled import tariffs on multiple drugs and raw materials: in 2019, the temporary import tariff rates for anticancer drug raw materials such as oxaliplatin, carboplatin, nedaplatin, and cisplatin were adjusted to zero; In 2020, zero tariff will be imposed on the drugs for asthma treatment and the raw materials Enggliptin, Liggliptin and Viggliptin for the production of new diabetes drugs; In 2021, zero tariffs will be imposed on the raw materials of the second batch of anti-cancer drugs and rare disease drugs; In 2022, zero tariffs will be implemented on the new anti-cancer drug radium chloride injection. Not only drugs are included in the "zero tariff" list, but this plan also clearly reduces import tariffs on lithium chloride, cobalt carbonate, low arsenic fluorite, as well as sweet corn, coriander, burdock seeds and other commodities, with temporary import tariffs reaching zero. Experts analyze that commodities such as lithium chloride and cobalt carbonate are key raw materials in the new energy vehicle industry, while fluorite is an important mineral resource. The significant reduction in import tariffs on these products will help support enterprises in allocating resources globally, reducing production costs, and enhancing the resilience of the industrial and supply chains. The tariff reduction and increase this time
Edit：Hou Wenzhe Responsible editor：WeiZe
Source：people.cn
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Economy
Recommended Reading Change it 
Home
